Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Peter Traber Insider Profile
4 Followers
Peter Traber, President & CEO at Galectin Therapeutics, holds 451.83K shares in Cartesian Therapeutics (Ticker: RNAC), holds 149.19K shares in Lisata Therapeutics (Ticker: LSTA), holds 107.33K shares in Galectin Therapeutics (Ticker: GALT). Most recently, Peter Traber Sold ― shares of Cartesian Therapeutics on Sep 26, 2023 for an estimated value of 747.30.
Peter Traber Galectin Therapeutics (GALT)President & CEO
Galectin Therapeutics (GALT)
President & CEO
Ranked #12,196 out of 98,501 Corporate Insiders
Profitable Transactions
7 out of 13 Profitable Transactions
Average Return
+11.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Peter Traber holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Oct 15, 2021 - Oct 15, 2022
Return:+64.10%
The most profitable trade made by Peter Traber
Peter Traber's Trading History
Galectin Therapeutics
Jun 15, 2018
President & CEO
Uninformative Sell
751.00K
$362.79K
Cartesian Therapeutics
Sep 26, 2023
CMO
Informative Sell
747.30
$8.36M
Lisata Therapeutics
Jan 12, 2022
Director
Uninformative Buy
―
$414.75K
List of latest transactions for each holding click on a transaction to see Peter Traber's performance on stock
You May Also Like
Peter Traber insider profile FAQ
What is the percentage of profitable transactions made by Peter Traber?
The percentage of profitable transactions made by Peter Traber is 54%.
What is the average return per transaction made by Peter Traber?
The average return per transaction made by Peter Traber is 11.60%.
What stocks does Peter Traber hold?
Peter Traber holds: GALT, RNAC, LSTA stocks.
What was Peter Traber’s latest transaction?
Peter Traber latest transaction was an Informative Sell of $747.30.
What was Peter Traber's most profitable transaction?
Peter Traber’s most profitable transaction was an Informative Sell of RNAC stock on October 15, 2021. The return on the trade was 64.10%.
What is Peter Traber's role in Galectin Therapeutics?
Peter Traber's role in Galectin Therapeutics is President & CEO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.